WCG Blog
Insights from the WIRB-Copernicus Group
-
Read PostNew Study Uncovers the $966 Billion Economic Impact of Rare Diseases
-
Read PostBest Practices for Research Sites: Effectively Using Patient Recruitment Advertising Dollars
- Download Report
-
Read PostData and Biorepository Management During a Pandemic
-
Read PostInformed Consent: An IRB Perspective on Navigating the New Normal
-
Read PostNew Normal or Not, Safety Reporting Matters
-
Read PostThere is Value to Patients When Independent Sites Offer Clinical Trials
-
Read PostCOVID-19 Changed Everything: Now Contracts and Budgets Need to Catch Up
-
Read PostFour Tips For Navigating Patient Recruitment During COVID-19
-
Read PostWCG: Advocating for Patients in a time of COVID-19
-
Read PostCOVID-19 Insights from Former FDA Commissioner, Scott Gottlieb, MD
The coronavirus has spread beyond the point of containment, and there’s a looming shortage of personal protective equipment. Hear insights from former FDA Commissioner, Scott Gottlieb, MD.
-
Read PostCOVID-19 Preparedness for Health Care Institutions with Dr. Paul Biddinger of Massachusetts General Hospital
-
Read PostEssential Considerations for CTMS Integrations and Data Migrations
-
Read PostNIH Launches NExTRAC to Advise on Emerging Biotechnologies
-
Read PostBe the Site of Choice
In early October, over hundreds of representatives of clinical research sites and members from biopharmaceutical companies came together for WCG’s Global Research Network™ Be the Site of Choice Event.
-
Read PostAn Overview of the Recent SACHRP Recommendations Around Payments in Clinical Research
-
Read PostWhat if Patients and Patient Advocates Spoke About Clinical Trial Participation and the Key Issues that Affected Trial Participation?
A forum to gather Patient Advocacy Groups, their constituents, and key stakeholders in drug development to advance and insist upon meaningful change in clinical research.
-
Read PostIn the Gut, In the Environment, On the iPad: Emerging Developments in Autism Research
We are, at last, beginning to better understand the broad range of phenotypic differences in what we classify as autism spectrum disorders.
-
Read PostLessons Learned from 600+ Expert Committee Members
We asked our network of over 600 experts to share with us what they think makes an expert committee successful.
-
Read PostYour 5 Questions About Enrollment Assistants Answered
-
Read PostWhat You Don’t Know About Patient Recruitment Can Impede the Success of Your Trial
-
Loading More...
